{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:02:23Z","timestamp":1781924543436,"version":"3.54.5"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.03175","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T12:30:13Z","timestamp":1547814613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection"],"prefix":"10.3389","volume":"9","author":[{"given":"Felicity","family":"Hartnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Kopycinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shokouh","family":"Makvandi-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Swadling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cicconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Del Sorbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Sbrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ventzislav","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clair M.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran","family":"Bannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Folgori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrd4050","article-title":"von. Novel therapies for hepatitis C \u2014 one pill fits all?","volume":"12","author":"Manns","year":"2013","journal-title":"Nat Rev Drug Discov."},{"key":"B4","year":"2017","journal-title":"Global Hepatitis Report 2017"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","author":"Trickey","year":"2017","journal-title":"Lancet HIV"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/cid\/cis694","article-title":"Hepatitis C virus infections in the Swiss HIV cohort study: a rapidly evolving epidemic","volume":"55","author":"Wandeler","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/cid\/ciw219","article-title":"Management of hepatitis C\/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy","volume":"63","author":"Wyles","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jhep.2017.03.038","article-title":"Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990\u20132014","volume":"67","author":"Santen","year":"2017","journal-title":"J Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jhep.2015.04.019","article-title":"High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013","volume":"63","author":"Kovari","year":"2015","journal-title":"J Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e4727","DOI":"10.1097\/MD.0000000000004727","article-title":"Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: role of HCV coinfection","volume":"95","author":"Alejos","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0156213","DOI":"10.1371\/journal.pone.0156213","article-title":"The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals?","volume":"11","author":"Stone","year":"2016","journal-title":"PLoS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.virusres.2018.02.016","article-title":"Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies","volume":"248","author":"Bartenschlager","year":"2018","journal-title":"Virus Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41669-016-0009-9","article-title":"The potential cost-effectiveness of HIV vaccines: a systematic review","volume":"1","author":"Adamson","year":"2017","journal-title":"Pharmacoecon Open."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1016\/j.vaccine.2010.01.065","article-title":"Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8 T cells","volume":"28","author":"Yashima","year":"2010","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial","volume":"94","author":"Idoko","year":"2014","journal-title":"Tuberculosis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3389\/fimmu.2017.01551","article-title":"Safety and immunogenicity of malaria vectored vaccines given with routine expanded program on immunization vaccines in gambian infants and neonates: a randomized controlled trial","volume":"8","author":"Mensah","year":"2017","journal-title":"Front Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/infdis\/jiw024","article-title":"Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: a randomized trial","volume":"213","author":"Zaman","year":"2016","journal-title":"J Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.coviro.2017.03.014","article-title":"Designing an HCV vaccine: a unique convergence of prevention and therapy?","volume":"23","author":"Walker","year":"2017","journal-title":"Curr Opin Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu Rev Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1084\/jem.20030239","article-title":"Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection","volume":"197","author":"Shoukry","year":"2003","journal-title":"J Exp Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nri3478","article-title":"Unravelling the mechanisms of durable control of HIV-1","volume":"13","author":"Walker","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1128\/JVI.71.10.7711-7718.1997","article-title":"Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus","volume":"71","author":"Johnson","year":"1997","journal-title":"J Virol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coi.2016.05.014","article-title":"Viral vectors as vaccine platforms: from immunogenicity to impact","volume":"41","author":"Ewer","year":"2016","journal-title":"Curr Opin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1080\/14760584.2017.1394842","article-title":"Chimpanzee adenoviral vectors as vaccines \u2013 challenges to move the technology into the fast lane","volume":"16","author":"Vitelli","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"Borthwick","year":"2014","journal-title":"Mol Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus Ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS ONE"},{"key":"B35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/104303404322886147","article-title":"Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines","volume":"15","author":"Aste-Am\u00e9zaga","year":"2004","journal-title":"Hum Gene Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1093\/nar\/gkq871","article-title":"Optimizing the noise versus bias trade-off for illumina whole genome expression bead chips","volume":"38","author":"Shi","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/vaccines4030027","article-title":"Highly-Immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection","volume":"4","author":"Swadling","year":"2016","journal-title":"Vaccines"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0176418","DOI":"10.1371\/journal.pone.0176418","article-title":"Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines","volume":"12","author":"Borthwick","year":"2017","journal-title":"PLoS ONE"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1089\/aid.2006.22.1081","article-title":"A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects","volume":"22","author":"Tobery","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.immuni.2015.11.012","article-title":"Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures","volume":"43","author":"Nakaya","year":"2015","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J Infect Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"key":"B46","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector ebola vaccine","volume":"376","author":"Ledgerwood","year":"2014","journal-title":"N Engl J Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1128\/JVI.76.12.6104-6113.2002","article-title":"Comprehensive analysis of CD8+-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities","volume":"76","author":"Lauer","year":"2002","journal-title":"J Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/00822942-200504040-00002","article-title":"Los alamos hepatitis C immunology database","volume":"4","author":"Yusim","year":"2005","journal-title":"Appl Bioinformatics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1084\/jem.20062363","article-title":"Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses","volume":"204","author":"Precopio","year":"2007","journal-title":"J Exp Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1003404","DOI":"10.1371\/journal.ppat.1003404","article-title":"HIV-1 Vaccine-induced T-cell reponses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1","volume":"9","author":"Hertz","year":"2013","journal-title":"PLoS Pathog."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4049\/jimmunol.174.2.1037","article-title":"Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence","volume":"174","author":"Harari","year":"2005","journal-title":"J Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood","volume":"107","author":"Betts","year":"2006"},{"key":"B55","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines","volume":"28","author":"Miller","year":"2008","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.1128\/JVI.80.10.4705-4716.2006","article-title":"Expansion and diversification of virus-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara\/HIV-1 gag vaccine","volume":"80","author":"Dorrell","year":"2006","journal-title":"J Virol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4049\/jimmunol.176.1.200","article-title":"The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity","volume":"176","author":"Yang","year":"2006","journal-title":"J Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0005527","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Negl Trop Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e67922","DOI":"10.1371\/journal.pone.0067922","article-title":"Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A","volume":"8","author":"Matsumiya","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T22:31:07Z","timestamp":1606084267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2018.03175"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.03175","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"article-number":"3175"}}